Palisade Bio, Inc. (NASDAQ:PALI) Receives $13.25 Average Price Target from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.3333.

A number of brokerages have weighed in on PALI. Clear Str upgraded Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Stifel Nicolaus started coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. B. Riley Financial initiated coverage on shares of Palisade Bio in a research note on Friday, January 9th. They set a “buy” rating and a $7.00 price target on the stock. Piper Sandler started coverage on Palisade Bio in a report on Monday, December 29th. They set an “overweight” rating and a $25.00 price objective on the stock. Finally, Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th.

Palisade Bio Stock Up 1.8%

NASDAQ PALI opened at $2.01 on Tuesday. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.64. The stock has a market cap of $298.75 million, a P/E ratio of -0.95 and a beta of 1.53. The company’s 50-day simple moving average is $1.77 and its 200 day simple moving average is $1.69.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers acquired a new position in Palisade Bio in the fourth quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC bought a new stake in Palisade Bio in the fourth quarter valued at about $26,000. Virtu Financial LLC acquired a new position in Palisade Bio in the fourth quarter valued at about $28,000. Atom Investors LP acquired a new stake in shares of Palisade Bio in the 4th quarter valued at approximately $33,000. Finally, Barclays PLC acquired a new stake in Palisade Bio in the fourth quarter worth $35,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.